Executive management members and members of the Board of Directors buys shares and board member Shomit Ghose sells shares
September 14, 2021
Copenhagen, Denmark, 14 September 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today announces that Morten Albrechtsen (CEO), Andreas Kjær (CSO), Henrik Moltke (CFO), Mats Thorén (board member) and Micaela Sjökvist (board member) have purchased shares. Shomit Ghose (board member) has sold shares to pay income tax on his shareholdings in FluoGuide due to U.S. tax regulations.
|Overview of share transactions September 14, 2021, of members of the Board and Management|
|Number of shares||Average Share price***)||Shareholding after purchase||Votes and capital %|
|Member of Board and Management that has bought shares|
|Micaela Sjökvist, Board member||741||109.71||62,163||0.55%|
|Mats Thorén, Board member||741||109.71||741||0.01%|
|Henrik Moltke, CFO||1,216||109.71||1,216||0.01%|
|Life Science IVS*)||1,216||109.71||2,126,107||18.78%|
|Wexotec ApS **)||1,216||109.71||1,488,610||13.15%|
|Member of Board that has sold shares||Number of shares||Average Share price***)||Shareholding after sale||Votes and capital %|
|*) Owned by Andreas Kjær, CSO, Board member|
|**) Owned by Morten Albrechtsen, CEO|
***) Trade between 30 August and 13 September 2021
“Due to the success of FluoGuide, I have to pay tax on my shareholdings of FluoGuide and I have decided to finance this by selling some of my shares in FluoGuide”, says Shomit Ghose, member of the Board of Directors of FluoGuide and continues: “I have a strong confidence in FluoGuide with a visionary leadership, promising technology and execution power I have rarely seen even compared to a U.S. standard. I am very proud to be part of its exciting development and committed to contribute to fully utilizing FluoGuide’s data utilization potential in advance surgical guidance.”
The transactions are reported to The Danish Financial Supervisory Authority (Danish: “Finanstilsynet”) in accordance with current regulations.
Morten Albrechtsen, CEO
Phone: +45 24 25 62 66
Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.